Global Automated Breast Ultrasound Systems (ABUS) Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By End User;
Hospitals and Diagnostic Imaging Laboratories.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Automated Breast Ultrasound Systems (ABUS) Market (USD Million), 2021 - 2031
In the year 2023, the Global Automated Breast Ultrasound Systems (ABUS) Market was valued at USD 1,603.24 million. The size of this market is expected to increase to USD 2,958.30 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 8.5%.
The Global Automated Breast Ultrasound Systems (ABUS) Market is experiencing significant growth and transformation, driven by the increasing prevalence of breast cancer, advancements in medical imaging technology, and growing awareness about the importance of early detection and diagnosis. Automated Breast Ultrasound Systems (ABUS) have emerged as valuable tools in breast cancer screening, offering complementary imaging to mammography for women with dense breast tissue and providing clinicians with clearer visualization of breast lesions.
ABUS technology automates the ultrasound imaging process, enabling consistent and reproducible scans of the entire breast without operator dependency. This automation enhances the efficiency of breast cancer screening programs and improves the detection of small, occult tumors that may be missed by mammography alone, especially in women with dense breast tissue. ABUS has gained traction as an adjunctive screening modality in conjunction with mammography, particularly for women at higher risk or with dense breast tissue.
The market for Automated Breast Ultrasound Systems (ABUS) is witnessing robust growth, driven by factors such as increasing breast cancer incidence, rising demand for personalized and risk-based screening strategies, and advancements in imaging technology. Additionally, favorable reimbursement policies and guidelines endorsing the use of ABUS as a supplemental screening tool further support market expansion. Ongoing research and development efforts focused on improving ABUS technology, enhancing image quality, and integrating artificial intelligence (AI) for image interpretation are expected to drive innovation and adoption in the coming years.
Geographically, the Global Automated Breast Ultrasound Systems (ABUS) Market spans regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, each presenting unique opportunities and challenges. North America holds a significant share of the market, driven by robust healthcare infrastructure, early adoption of advanced imaging technologies, and supportive regulatory frameworks. The Asia Pacific region is poised to witness accelerated growth due to increasing healthcare expenditure, rising breast cancer awareness initiatives, and expanding access to medical imaging services.
Global Automated Breast Ultrasound Systems (ABUS) Market Recent Developments
-
In July 2024, Delphinus Medical Technologies, Inc. installed its SoftVue breast ultrasound tomography system at West Jefferson Medical Center in Louisiana. This advanced imaging technology is specifically designed for dense breast screening, providing a comfortable examination experience without compression or radiation.
-
In February 2023, iSono Health, a medical technology company, entered into a distribution agreement with Abdul Latif Jameel Health to launch its 3D ultrasound portable breast imaging scanner, known as the ATUSA, in the Middle East and Africa. This partnership designates Abdul Latif Jameel Health as the exclusive distributor of the ATUSA scanner in the Global South, which is expected to significantly enhance iSono Health's geographical footprint and strengthen its brand image in these regions.
Segment Analysis
These are primary healthcare facilities where diagnostic imaging services, including breast ultrasound examinations, are routinely conducted. Hospitals and clinics serve as major consumers of automated breast ultrasound systems, providing breast cancer screening, diagnosis, and monitoring services to patients.
Specialized imaging centers dedicated to breast health and women's imaging services often utilize automated breast ultrasound systems as part of their comprehensive diagnostic capabilities. These centers may offer breast ultrasound screenings, supplemental imaging for patients with dense breasts or high-risk factors, and ultrasound-guided biopsies.These specialized clinics focus specifically on breast health and provide comprehensive breast care services, including screening, diagnostic evaluations, counseling, and follow-up care. Automated breast ultrasound systems are integral to the diagnostic armamentarium of breast health clinics, enabling efficient and accurate assessment of breast abnormalities.
Ambulatory Surgical Centers (ASCs), these outpatient facilities offer a range of surgical and medical procedures, including breast biopsies and minimally invasive interventions guided by ultrasound imaging. Automated breast ultrasound systems may be used in ASCs for preoperative planning, intraoperative guidance, and postoperative surveillance in breast surgery cases.
Geographical segmentation divides the market based on regional and global distribution, allowing for a detailed analysis of market trends, regulatory landscapes, and adoption patterns across different geographic regions. Key geographical regions may include , North America, A mature market for automated breast ultrasound systems, characterized by high adoption rates, advanced healthcare infrastructure, and stringent regulatory standards. The United States, in particular, accounts for a significant share of the global ABUS market.
Global Automated Breast Ultrasound Systems (ABUS) Segment Analysis
In this report, the Global Automated Breast Ultrasound Systems (ABUS) Market has been segmented by End User and Geography.
Global Automated Breast Ultrasound Systems (ABUS) Market, Segmentation by End User
The Global Automated Breast Ultrasound Systems (ABUS) Market has been segmented by End User into Hospitals and Diagnostic Imaging Laboratories.
Hospitals serve as pivotal healthcare institutions providing a wide array of medical services, including diagnostic imaging for breast health. Within hospitals, radiology departments and breast imaging centers utilize ABUS systems as part of their comprehensive breast cancer screening and diagnostic protocols. These systems enable healthcare professionals to conduct efficient and accurate ultrasound examinations of the breast, aiding in the detection and characterization of breast lesions, particularly in women with dense breast tissue. Hospitals play a crucial role in providing ABUS services to a broad patient population, ranging from routine screening to diagnostic evaluations and surveillance for breast abnormalities.
Diagnostic Imaging Laboratories, also known as imaging centers or clinics, specialize in providing diagnostic imaging services to patients referred by healthcare providers. These facilities offer a range of imaging modalities, including mammography, ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT), to support the early detection and diagnosis of various medical conditions. Within diagnostic imaging laboratories, ABUS systems are utilized for breast ultrasound examinations, particularly in cases where mammography may be inconclusive or when additional imaging is warranted for women with dense breast tissue. These facilities may offer ABUS as a standalone service or as part of a comprehensive breast imaging program, providing patients with access to advanced screening and diagnostic technologies in a convenient outpatient setting.
Global Automated Breast Ultrasound Systems (ABUS) Market, Segmentation by Geography
In this report, the Global Automated Breast Ultrasound Systems (ABUS) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Automated Breast Ultrasound Systems (ABUS) Market Share (%), by Geographical Region, 2024
North America represents a significant market for ABUS systems, characterized by high adoption rates, advanced healthcare infrastructure, and robust breast cancer screening programs. The United States, in particular, accounts for a substantial share of the North American ABUS market, driven by increasing awareness of breast health, rising prevalence of breast cancer, and technological advancements in imaging technologies. Moreover, favorable reimbursement policies and government initiatives to promote breast cancer screening contribute to market growth in this region.
Europe is another key region in the Global ABUS Market, characterized by a growing emphasis on early detection and diagnosis of breast cancer, particularly in countries like Germany, France, and the United Kingdom. The European ABUS market benefits from government-sponsored breast cancer screening programs, advancements in healthcare technology, and a strong focus on women's health initiatives. Additionally, collaborations between healthcare institutions, research organizations, and industry players drive innovation and market expansion in Europe.
Asia Pacific exhibits significant growth potential in the ABUS market, fueled by increasing healthcare expenditure, rising awareness of breast cancer screening, and improving access to healthcare services across emerging economies. Countries such as China, Japan, and India are witnessing growing adoption of ABUS systems, driven by the rising burden of breast cancer and efforts to enhance cancer detection rates through early screening and diagnosis. Moreover, strategic partnerships, market expansion initiatives, and technological advancements contribute to the growth of the ABUS market in the Asia Pacific region.
The Middle East and Africa region presents opportunities for market penetration and expansion of ABUS systems, driven by rising healthcare investments, improving healthcare infrastructure, and growing awareness of breast cancer screening initiatives. Countries in the Gulf Cooperation Council (GCC) region, such as Saudi Arabia, UAE, and Qatar, are witnessing increased adoption of advanced medical technologies, including ABUS systems, to address the growing burden of breast cancer and improve women's health outcomes.
Latin America represents a growing market for ABUS systems, characterized by increasing healthcare investments, rising prevalence of breast cancer, and initiatives to improve cancer screening and diagnosis. Countries like Brazil, Mexico, and Argentina are key contributors to the Latin American ABUS market, driven by government-led healthcare initiatives, expanding healthcare coverage, and partnerships with international healthcare organizations.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Automated Breast Ultrasound Systems (ABUS) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunities Analysis
Drivers:
- Rising Breast Cancer Incidence
- Patient Comfort and Safety
-
Advantages Over Traditional Breast Imaging - Automated Breast Ultrasound Systems (ABUS) offer several distinct advantages over traditional imaging modalities, driving their adoption and utilization in clinical practice. These advantages stem from the unique capabilities and features of ABUS technology, which complement and enhance the benefits of existing breast imaging techniques such as mammography and magnetic resonance imaging (MRI).
Firstly, ABUS provides supplementary imaging for women with dense breast tissue. Dense breast tissue can mask potential abnormalities on mammograms, leading to false-negative results and missed diagnoses. ABUS serves as a complementary screening tool, offering additional information beyond mammography by providing high-resolution ultrasound images of the entire breast. This improves the detection of small masses, architectural distortions, and other subtle abnormalities that may be obscured on mammograms in women with dense breasts.
Secondly, ABUS offers a radiation-free imaging alternative. Unlike mammography, which utilizes ionizing radiation to produce images of the breast tissue, ABUS relies on ultrasound technology that does not involve radiation exposure. This makes ABUS a safe and suitable option for breast cancer screening, particularly for women with a history of radiation exposure, such as those undergoing repeated mammographic screenings or younger women with genetic predispositions to breast cancer.
ABUS enhances imaging workflow efficiency and reproducibility. The automated nature of ABUS systems allows for standardized and consistent breast scans, reducing operator variability and improving image quality. ABUS examinations can be performed quickly, with minimal patient discomfort, making them suitable for high-volume screening settings such as breast cancer screening programs or routine surveillance for women with elevated breast cancer risk.
Restraints:
- High Cost of ABUS Systems
- Limited Reimbursement Policies
-
Operator Training and Expertise - The complex nature of breast anatomy, the variability in breast tissue composition among individuals, and the diverse spectrum of breast abnormalities necessitate specialized training for healthcare professionals to acquire the necessary skills for interpreting ABUS images accurately. Unlike traditional 2D mammography, which is widely performed and interpreted by radiologists with specialized training in breast imaging, ABUS requires additional expertise in ultrasound imaging interpretation, particularly in the context of breast pathology.
Operator training and expertise are essential to ensure the proper positioning of the ABUS transducer, optimal image acquisition techniques, and accurate interpretation of ultrasound findings. Inadequate training or lack of experience may lead to suboptimal image quality, misinterpretation of findings, and potentially missed or misdiagnosed breast lesions, compromising the diagnostic accuracy and effectiveness of ABUS as a screening tool.
Maintaining proficiency in ABUS interpretation requires ongoing education and skill development to stay abreast of evolving technology, imaging protocols, and diagnostic criteria. Continuous training programs, proficiency testing, and quality assurance measures are necessary to uphold standards of practice and ensure consistent, high-quality performance across different healthcare settings.
The need for specialized training and expertise in ABUS interpretation may present challenges for healthcare institutions in terms of resource allocation, staff training, and workflow optimization. It may require dedicated efforts to train radiologists, sonographers, and other healthcare professionals in ABUS interpretation, potentially leading to increased operational costs and workflow disruptions.
Opportunities:
- Advancements in Imaging Technology
- Increasing Adoption of Breast Density Notification Laws
-
Growing Preference for Non-Radiation-Based Screening Modalities - The Global Automated Breast Ultrasound Systems (ABUS) Market presents a significant opportunity driven by the growing preference for non-radiation-based screening modalities, particularly in breast cancer detection and diagnosis. This shift in preference is fueled by several factors and presents a compelling opportunity for the ABUS market to address unmet needs and expand its reach in breast imaging.
One key driver of this trend is the increasing awareness of the potential risks associated with radiation exposure from traditional breast imaging modalities such as mammography. While mammography remains a gold standard for breast cancer screening, concerns about radiation exposure, particularly among younger women and those with genetic predispositions to breast cancer, have led to a growing demand for alternative screening options.
Automated Breast Ultrasound Systems (ABUS) offer a radiation-free imaging modality that complements mammography in breast cancer screening and detection. ABUS utilizes sound waves to create detailed images of the breast tissue, making it an attractive option for women seeking non-invasive and radiation-free screening methods. This growing preference for non-radiation-based modalities positions ABUS as a valuable adjunct to mammography, particularly for women with dense breast tissue, where mammography may be less sensitive and more challenging to interpret.
Advancements in ABUS technology have led to improvements in image quality, workflow efficiency, and interpretation capabilities, enhancing the utility and effectiveness of ABUS as a standalone screening tool or as a supplemental imaging modality. Innovations such as automated 3D whole-breast ultrasound and artificial intelligence-driven image analysis algorithms have further strengthened the diagnostic capabilities of ABUS, making it an increasingly viable option for breast cancer screening in diverse patient populations.
The growing emphasis on personalized medicine and patient-centered care also drives the preference for non-radiation-based screening modalities like ABUS. Healthcare providers and patients alike recognize the importance of tailored screening approaches that take into account individual risk factors, preferences, and medical histories. ABUS offers a non-invasive, patient-friendly option for breast cancer screening, particularly for women who may be reluctant to undergo mammography due to radiation concerns or discomfort.
Competitive Landscape Analysis
Key players in Global Automated Breast Ultrasound Systems (ABUS) Market include:
- GE Healthcare
- Hitachi Ltd
- SonoCine Inc
- Philips Healthcare
- Siemens Healthineers
- Supersonic Imagine
- Toshiba Corporation
- QT Ultrasound LLC
- Adaltis S.r.l.
- Volpara Health Technologies
- Delphinus Medical Technologies, Inc
- General Electric Company
- Hologic, Inc
- Telemed Systems, Inc
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By End User
- Market Snapshot, By Region
- Global Automated Breast Ultrasound Systems (ABUS) Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Rising Breast Cancer Incidence
-
Patient Comfort and Safety
-
Advantages Over Traditional Breast Imaging
-
- Restraints
-
High Cost of ABUS Systems
-
Limited Reimbursement Policies
-
Operator Training and Expertise
-
- Opportunities
-
Advancements in Imaging Technology
-
Increasing Adoption of Breast Density Notification Laws
-
Growing Preference for Non-Radiation-Based Screening Modalities
-
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Automated Breast Ultrasound Systems (ABUS) Market, By End User, 2021 - 2031 (USD Million)
-
Hospitals
-
Diagnostic Imaging Laboratories
-
- Global Automated Breast Ultrasound Systems (ABUS) Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Automated Breast Ultrasound Systems (ABUS) Market, By End User, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- GE Healthcare
- Hitachi Ltd
- SonoCine Inc
- Philips Healthcare
- Siemens Healthineers
- Supersonic Imagine
- Toshiba Corporation
- QT Ultrasound LLC
- Adaltis S.r.l.
- Volpara Health Technologies
- Delphinus Medical Technologies, Inc
- General Electric Company
- Hologic, Inc
- Telemed Systems, Inc
- Company Profiles
- Analyst Views
- Future Outlook of the Market